Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells - Archive ouverte HAL Access content directly
Journal Articles Journal for Immunotherapy of Cancer Year : 2013

Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells

(1) , (2) , (1) , (1) , (1) , (1) , (2)
1
2

Domains

Life Sciences [q-bio] Immunology
Fichier principal
Vignette du fichier
2051-1426-1-S1-P176.pdf (140.65 Ko) Télécharger le fichier
Vignette du fichier
2051-1426-1-S1-P176.xml (4.65 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other

Ed. BMC  : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-00881032

Submitted on : Thursday, November 7, 2013-1:04:54 PM

Last modification on : Wednesday, November 10, 2021-3:32:02 PM

Long-term archiving on: Saturday, February 8, 2014-7:05:09 AM

Download

Dates and versions

inserm-00881032 , version 1 (07-11-2013)

Identifiers

  • HAL Id : inserm-00881032 , version 1

Cite

Sandrine Valsesia-Wittmann, Beatrice Clemenceau, Anne-Catherine Jallas, Jean-Yves Blay, Aurelien Marabelle, et al.. Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells. Journal for Immunotherapy of Cancer, 2013, 1 (Suppl 1), pp.P176. ⟨inserm-00881032⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM CNRS UNAM CRCNA
167 View
186 Download

Share

Gmail Facebook Twitter LinkedIn More